EMA — authorised 26 June 2023
- Marketing authorisation holder: Bristol-Myers Squibb Pharma EEIG
- Status: approved
🇪🇺 Camzyos in European Union
EMA authorised Camzyos on 26 June 2023
Marketing authorisations
EMA — authorised 26 June 2023
- Application: EMEA/H/C/005457
- Marketing authorisation holder: Bristol-Myers Squibb Pharma EEIG
- Local brand name: Camzyos
- Indication: Treatment of symptomatic obstructive hypertrophic cardiomyopathy.
- Status: approved
Camzyos in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Cardiovascular approved in European Union
Frequently asked questions
Is Camzyos approved in European Union?
Yes. EMA authorised it on 26 June 2023; EMA authorised it on 26 June 2023.
Who is the marketing authorisation holder for Camzyos in European Union?
Bristol-Myers Squibb Pharma EEIG holds the EU marketing authorisation.